DWDavid F. Woodward

David F. Woodward

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David F. Woodward has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Deletion of the gene encoding prostamide/prostaglandin F synthase reveals an important role in regulating intraocular pressure

    by Jacques A Bertrand, David F Woodward, Joseph M Sherwood, Alice Spenlehauer, Cristoforo Silvestri, Fabiana Piscitelli, Vincenzo Di Marzo, Maya Yamazaki, Kenji Sakimura, Yoko Inoue, et al.


  • The role of EP 2 receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1

    by Jacques A Bertrand, David F Woodward, Joseph M Sherwood, Jenny W Wang, Darryl R Overby

    Background: A single application of JV-GL1 substantially lowers non-human primate intraocular pressure (IOP) for about a week, independent of dose. This highly protracted effect does not correlate with its ocular biodisposition or correlate with the once-daily dosing regimen for other prostanoid EP 2 receptor agonists such as trapenepag or omidenepag. The underlying pharmacological mechanism for the multiday extended activity of JV-GL1 is highly intriguing. The present studies were intended to determine EP 2 receptor involvement in mediating the long-term ocular hypotensive activity of JV-GL1 by using mice genetically deficient in EP 2 receptors. Methods: The protracted IOP reduction produced by JV-GL1 was investigated in C57BL/6J and EP 2 receptor knock-out mice (B6.129- Ptger2 tm1Brey /J; EP 2 KO). Both ocular normotensive and steroid-induced ocular hypertensive (SI-OHT) mice were studied. IOP was measured tonometrically under general anaesthesia. Aqueous humour outflow facility was measured ex vivo using iPerfusion in normotensive C57BL/6J mouse eyes perfused with 100 nM de-esterified JV-GL1 and in SI-OHT C57BL/6J mouse eyes that had received topical JV-GL1 (0.01%) 3 days prior. Results: Both the initial 1-day and the protracted multiday effects of JV-GL1 in the SI-OHT model for glaucoma were abolished by deletion of the gene encoding the EP 2 receptor. Thus, JV-GL1 did not lower IOP in SI-OHT EP 2 KO mice, but in littermate SI-OHT EP 2 WT control mice, JV-GL1 statistically significantly lowered IOP for 4–6 days. Conclusions: Both the 1-day and the long-term effects of JV-GL1 on IOP are entirely EP 2 receptor dependent.


  • Open Access

    A Second Generation Prostanoid Receptor Antagonist Acting at Multiple Receptor Subtypes

    by David F. Woodward, Jenny W. Wang, Clayton S. Spada, Robert W. Carling, Jose L. Martos, Simon Pettit, Jussi Kangasmetsa, L. David Waterbury, Matthew Lawrence, Wenzheng Hu, et al.

    It has previously been reported that a prototypical compound (AGN 211377), which blocks pro-inflammatory prostanoid receptors (DP1, DP2, EP1, EP4, FP, TP) and leaves open IP and EP2 receptors so that their anti-inflammatory properties could be exerted, produced superior inhibitory effects on cytokine release from human macrophages compared to cyclooxygenase (COX) inhibitors. This favorable activity profile translated into animal studies, with AGN 211377 exceeding the level of inhibition afforded by COX inhibition. AGN 211377 was not, however, a practical drug candidate, having poor bioavailability and cost of goods concerns. Compound 1 (designated AGN 225660) represents a second-generation compound with an entirely different “druggable” core structure. Such a dramatic change in chemical scaffold created uncertainty with respect to matching the effects of AGN 211377. AGN 225660 inhibited RANTES, IL-8, and MCP-1 secretion by at least 50%, from TNFα activated human macrophages. Although AGN 225660 reduced TNFα-evoked MCP-1 release from human monocyte-derived macrophages, it increased LPS-induced MCP-1 secretion (up to 2-fold) from human monocyte-derived dendritic cells. However, AGN 225660 inhibited the release of IL12p 70 and IL-23 from human monocyte-derived dendritic cells stimulated by LPS by more than 70%. This effect of AGN 225660 was reproduced in part by the prototype compound AGN 211377 and a combination of selective DP1, EP1, EP4, FP, and TP antagonists. These findings suggest important effects on T cell skewing and disease modification by this class of therapeutic agents. AGN 225660 exhibited good ocular bioavailability and was active in reducing ocular inflammation associated with phacoemulsification surgery, LPS, and arachidonic acid induced uveitis.


  • Open Access

    Distribution and Function of Prostaglandin E2 Receptors in Mouse Uterus: Translational Value for Human Reproduction

    by Deborah P. Fischer, Anna L. Griffiths, Sylvia Lui, Uzmah J. Sabar, Diane Farrar, Peter J. O’dOnovan, David F. Woodward, Kay M. Marshall

    Prostaglandin (PG) E analogues are used clinically to ripen the cervix and induce labour. However, selective receptor agonists may have potential to improve induction response rates or manage unwanted uterine hypercontractility in conditions such as dysmenorrhoea and preterm labour. To characterise their therapeutic value, PGE2 analogues were used to investigate the functional EP receptor population in isolated human uterus. Responsiveness in mouse tissues was also examined to validate its use as a pre-clinical model. Uterine samples were obtained from mice at dioestrus (n=12), term gestation (n=14) and labour (n=12) and from the lower uterus of women undergoing hysterectomy (n=12) or Caesarean section (n=18). Vehicle and agonist effects were assessed using superfusion and immersion techniques. PGE2 evoked predominant excitatory responses in mouse and relaxation in human tissues. Selective EP4 agonists inhibited tissue activity in both non-pregnant species, whilst the EP2 mimetic CP533536 also attenuated uterine contractions throughout gestation. The uterotonic effects of the EP3/1 agonist sulprostone were more pronounced than the EP1 agonist ONO-D1-004, corresponding to abundant EP3 receptor expression in all samples. The contractile phenotype in mouse compared to human uteri may relate to regional differences as well as high expression of EP3 receptor transcripts. Similarities in non-pregnant and gestational tissues across species suggest that EP3 may represent a valuable translational drug target for preventing uterine hypercontractility by employing a selective antagonist. SIGNIFICANCE STATEMENT This research validates the use of non-pregnant mice for pre-clinical drug discovery of uterine EP receptor targets. To determine the utility of novel drugs and delivery systems at term pregnancy and labour, pharmacological agents interacting with EP3 receptors have clear translational value.


  • Open Access

    Gene deletion studies reveal a critical role for prostamide/prostaglandin F 2α synthase in prostamide F 2α formation

    by Jacques A Bertrand, David F. Woodward, Joseph M Sherwood, Alice Spenlehauer, Cristoforo Silvestri, Fabiana Piscitelli, Vincenzo Di Marzo, Maya Yamazaki, Kenji Sakimura, Kikuko Watanabe, et al.

    Prostamide / prostaglandin F synthase (PM/PGFS) is an enzyme with very narrow substrate specificity and is dedicated to the biosynthesis of prostamide and prostaglandin F 2α. The importance of this enzyme, relative to the aldoketoreductase (AKR) series, in providing functional tissue prostamide F 2α levels was determined by creating a line of PM/PGFS gene deleted mice. Deletion of the gene encoding PM/PGFS (fam213b) was accomplished by a two exon disruption. Prostamide F 2α levels in WT and PM/PGFS KO mice were determined by LC/MS/MS. Intraocular pressure was measured by tonometry and outflow facility was measured by the iPerfusion method in enucleated mouse eyes. Deletion of fam213b had no observed effect on behavior, appetite, or fertility. Intraocular pressure was significantly elevated by approximately 4 mmHg in PM/PGFS KO mice compared to littermate WT mice. No effect on pressure dependent outflow facility occurred, which is consistent with the typically reported prostanoid effect of increasing outflow through the unconventional pathway. The elevation of intraocular pressure caused by deletion of the gene encoding the PM/PGFS enzyme likely results from a diversion of the endoperoxide precursor pathway to provide increased levels of those prostanoids that raise intraocular pressure, namely prostaglandin D 2 (PGD 2 ), thromboxane A 2 (TxA 2 ). It follows that PM/PGFS may serve an important regulatory role in the eye by providing PGF 2α and prostamide F 2α to constrain the influence of those prostanoids that raise intraocular pressure.

  • Open Access

    The affinity, intrinsic activity and selectivity of a structurally novel EP 2 receptor agonist at human prostanoid receptors

    by R A Coleman, A J Woodrooffe, K L Clark, C B Toris, S Fan, J W Wang, D F Woodward

    Background and Purpose: Prostanoid EP 2 receptor agonists exhibit several activities including ocular hypotension, tocolysis and anti‐inflammatory activity. This report describes the affinity and selectivity of a structurally novel, non‐prostanoid EP 2 receptor agonist, PGN‐9856, and its therapeutic potential. Experimental Approach: The pharmacology of a series of non‐prostanoid EP 2 receptor agonists was determined according to functional and radioligand binding studies, mostly using human recombinant prostanoid receptor transfectants. The selectivity of PGN‐9856, as the preferred compound, was subsequently determined by using a diverse variety of non‐prostanoid target proteins. The therapeutic potential of PGN‐9856 was addressed by determining its activity in relevant primate cell, tissue and disease models. Key Results: PGN‐9856 was a selective and high affinity (pKi ≥ 8.3) ligand at human recombinant EP 2 receptors. In addition to high affinity binding, it was a potent and full EP 2 receptor agonist with a high level of selectivity at EP 1 , EP 3 , EP 4 , DP, FP, IP and TP receptors. In cells overexpressing human recombinant EP 2 receptors, PGN‐9856 displayed a potency (pEC 50 ≥ 8.5) and a maximal response (increase in cAMP) comparable to that of the endogenous agonist PGE 2 . PGN‐9856 exhibited no appreciable affinity (up 10 μM) for a range of 53 other receptors, ion channels and enzymes. Finally, PGN‐9856 exhibited tocolytic, anti‐inflammatory and long‐acting ocular hypotensive properties consistent with its potent EP 2 receptor agonist properties. Conclusions and Implications: PGN‐9856 is a potent, selective and efficacious prostanoid EP 2 receptor agonist with diverse potential therapeutic applications: tocolytic, anti‐inflammatory and notably anti‐glaucoma.


  • Prostaglandin E2-Glyceryl Ester: In Vivo Evidence for a Distinct Pharmacological Identity from Intraocular Pressure Studies

    by David F. Woodward, Neil J. Poloso, Jenny W. Wang

    Prostaglandin E2 (PGE2)-2-glyceryl ester is a COX-2 product of the endocannabinoid 2-arachidonyl glycerol. It is claimed as pharmacologically novel but this is complicated by rapid and irreversible isomerization to the 1(3) ester. For ocular studies, enzymatic hydrolysis of the ester moiety creates an additional complication. PG-glyceryl esters were stabilized to isomerization and hydrolysis by replacing the non-carbonyl O with NH, to form the serinolamide and propanediolamide as stable analogs of PG-2-glyceryl and -1(3) glyceryl esters, respectively. Intraocular pressure was measured in conscious dogs and conscious laser induced ocular hypertensive monkeys. Pharmacological studies involved stable transfectants for each of the human recombinant prostanoid receptors and the isolated feline iris for prostamide activity. PGE2-serinolamide and PGE2- propanediolamide were essentially inactive at all receptors except the EP3 receptor (E.C.50 ~500nM). This obliged elucidation of EP3 receptor involvement in the intraocular pressure response to these PGE2-glycyerl ester analogs. Since the EP3 receptor agonists, sulprostone and GR 63799, did not lower monkey intraocular pressure, a role for EP3 receptors in mediating the effects of PGE2-serinolamide and PGE2-propanediolamide is not indicated. PGE2-glyceryl ester (0.01% and 0.1%) substantially lowered intraocular pressure in monkeys. PGE2- propanediolamide was more efficacious than PGE2-serinolamide in lowering intraocular pressure in monkey eyes but both appeared equi-effective in dog eyes. PGE2-serinolamide dose-dependently (0.01- 0.1%) lowered intraocular pressure in both species but PGF2α-serinolamide was inactive. In conclusion, stable PGE2-glyceryl ester analogs lowered intraocular pressure. These findings are consistent with the presence of a PGE2-glyceryl ester specific recognition site in the eye.


  • Open Access

    Multitargeting of selected prostanoid receptors provides agents with enhanced anti‐inflammatory activity in macrophages

    by Jenny W. Wang, David F. Woodward, Jose L. Martos, Clive L. Cornell, Robert W. Carling, Philip J. Kingsley, Lawrence J. Marnett

    A polypharmacologic approach to prostanoid based anti‐inflammatory therapeutics was undertaken in order to exploit both the anti‐ and proinflammatory properties attributed to the various prostanoid receptors. Multitargeting of selected prostanoid receptors yielded a prototype compound, compound 1 (AGN 211377), that antagonizes prostaglandin D 2 receptors (DPs) DP 1 (49) and DP 2 (558), prostaglandin E 2 receptors (EPs) EP 1 (266) and EP 4 (117), prostaglandin receptor (FP) (61), and thromboxane A 2 receptor (TP) (11) while sparing EP 2 , EP 3 , and prostaglandin I 2 receptors (IPs); K b values (in nanomoles) are given in parentheses. Compound 1 evoked a pronounced inhibition of cytokine/chemokine secretion from lipopolysaccharide or TNF‐α stimulated primary human macrophages. These cytokine/chemokines included cluster of designation 40 receptor (CD40), epithelial‐derived neutrophil‐activating protein 78 (ENA‐78), granulocyte colony stimulating factor (G‐CSF), granulocyte macrophage colony stimulating factor (GM‐CSF), IL‐8, IL‐18, monocyte chemotactic protein‐1 (CCL2) (MCP‐1), tissue plasminogen activator inhibitor (PAI‐1), and regulated on activation, normal T cell expressed and secreted (RANTES). In contrast, the inhibitory effects of most antagonists selective for a single receptor were modest or absent, and selective EP 2 receptor blockade increased cytokine release in some instances. Compound 1 also showed clear superiority to the cyclooxygenase inhibitors diclofenac and rofecoxib. These findings reveal that blockade of multiple prostanoid receptors, with absent antagonism of EP 2 and IP, may provide more effective anti‐inflammatory activity than global suppression of prostanoid synthesis or highly selective prostanoid receptor blockade. These investigations demonstrate the first working example of prostanoid receptor polypharmacology for potentially safer and more effective anti‐inflammatory therapeutics by blocking multiple proinflammatory receptors while sparing those with antiinflammatory activity.—Wang, J. W., Woodward, D. F., Martos, J. L., Cornell, C. L., Carling, R. W., Kingsley, P. J., Marnett, L. J. Multitargeting of selected prostanoid receptors provides agents with enhanced anti‐inflammatory activity in macrophages. FASEB J. 30, 394‐404 (2016). www.fasebj.org


  • ChemInform Abstract: Synthesis of a Novel Series of 3-Oxo-2,4-dioxabicyclo(3.2.1)octanes: Additional Evidence for Two Thromboxane Receptor Subtypes.

    by R. M. Burk, T. S. Gac, M. E. Garst, L. L. Gibson, A. H. Krauss, C. E. Protzman, D. F. Woodward

    ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

  • Studies on the Ocular Hypotensive Effects of Prostaglandin F 2α Ester Prodrugs and Receptor Selective Prostaglandin Analogs

    by D.F. Woodward, M.F. Chan, J.A. Burke, A. Cheng-Bennett, G. Chen, C.E. Fairbairn, T. Gac, M.E. Garst, C. Gluchowski, L.J. Kaplan, et al.

    The use of natural prostaglandins (PG), such as PGD2, PGF2, PGF2α, and PGI2, for treating glaucoma is limited by their ocular side effects. One approach to achieve the required separation of ocular hypotensive activity from side effects is to employ ester prodrugs. From a novel series of 11- and 15-mono and 11,15-diacyl esters of PGF2α we identified prodrugs where PGF2α formation rates in the iris-ciliary body exceeded those in the conjunctiva, sciera, and corneal endothelium. Compared to PGF2α-1-isopropyl ester the ocular tissue hydrolysis rates of the 11-monopivaloyl, the 11,15-dipivaloyl ester and the 1,11-lactone were up to 1000 fold less. Despite this large disparity in hydrolysis rates, the pivaloyl esters and the 1,11-lactone were potent ocular hypotensives in our animal models. In studying prostaglandin analogs, we found that a diverse variety of prostanoid receptor selective agonists lowered intraocular pressure in dogs and/or monkeys. These included DP-, EP1-, EP2-, EP3-, and FP-receptor selective compounds. These findings were surprising and prompted us to re-examine the receptor selectivity of these agonists by radioligand binding studies. Using radiolabelled PGE2,17-phenyl PGF2α, and sulprostone we were able to confirm the selectivity of the agonists currently used for receptor characterization directly by radioligand binding competition studies. It appears that multiple prostanoid receptor subtypes may be involved in regulating intraocular pressure.